AORT

SEC Filing Summary: CryoLife, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for CryoLife, Inc. for the period ended September 30, 2002. The Company is a medical device and services firm specializing in human tissue preservation and implantable medical devices. The reporting period is dominated by the impact of an August 13, 2002, FDA Order requiring the recall and retention of non-valved cardiac, vascular, and orthopaedic tissues processed since October 3, 2001, due to alleged violations of federal regulations and contamination risks.

Key Financial Metrics

Note: The Company recorded a $22.7 million write-down of deferred preservation costs and a $1.4 million goodwill impairment in the third quarter of 2002.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 25% in the three months ended September 30, 2002, compared to the same period in 2001. Human tissue preservation services revenue dropped 43% (from $19.7M to $11.3M) due to the FDA recall and reduced demand.
• Profitability Reversal: The Company swung from a net income of $2.7 million in Q3 2001 to a net loss of $19.6 million in Q3 2002. This is primarily driven by the $22.7 million write-down of deferred preservation costs and increased legal/professional fees.
• Cost Structure: Cost of human tissue preservation services increased 241% year-over-year, largely due to the non-cash write-downs of impaired inventory.
• Workforce Reduction: The Company reduced its employee force by approximately 105 employees in September 2002, incurring $690,000 in severance costs.

Guidance, Outlook, and Risks

Management Commentary: Management anticipates a significant decrease in liquidity and revenues for the remainder of 2002 and into 2003. While an interim agreement with the FDA allows for limited distribution of cardiac and vascular tissues, demand remains suppressed due to adverse publicity. The Company expects to meet liquidity needs through September 30, 2003, utilizing existing cash, marketable securities, and expected tax refunds exceeding $10 million.

Key Risks and Contingencies:

• FDA Order & Recall: The recall of tissues processed since October 2001 has severely impacted the core business. There is no assurance that demand will return to pre-order levels even if compliance is achieved.
• Debt Covenant Default: The Company is in violation of debt coverage and net worth covenants on its Term Loan. The lender has notified the Company that the FDA Order constitutes an event of default but has elected not to declare it as of October 28, 2002. The entire Term Loan balance is classified as a current liability.
• Litigation: The Company faces 15 product liability cases, several putative class-action securities lawsuits, and a shareholder derivative suit. An accrual of $1.2 million has been recorded for insurance deductibles.
• SEC Investigation: The Company is subject to an informal SEC investigation regarding the disclosure of the FDA Order and related accounting issues.

Investor Verification Checklist

• Debt Status: Verify if the lender has formally declared an event of default on the $6.0 million Term Loan and if the $10 million line of credit remains inaccessible.
• FDA Agreement Renewal: Confirm the status of the interim operating agreement with the FDA (expiring November 7, 2002) and whether it will be extended or modified.
• Liquidity Runway: Assess the timing of the expected $10+ million in tax refunds and whether they are sufficient to cover operating losses and legal fees through 2003.
• Customer Retention: Evaluate the extent to which customers have permanently switched to competitors for tissue preservation services.
• Legal Exposure: Monitor the progression of the 15 product liability cases and the potential for judgments exceeding the $1.2 million insurance deductible accrual.